Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, United Kingdom; Department of Pathophysiology, University of Split School of Medicine and University Hospital of Split, Split, Croatia; Institute of Emergency Medicine of Split-Dalmatia County (ZHM SDZ), Split, Croatia.
Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, United Kingdom; Department of Cardiology, Royal Stoke Hospital, University Hospital North Midlands, Stoke-on-Trent, United Kingdom.
Am J Cardiol. 2019 Oct 15;124(8):1190-1197. doi: 10.1016/j.amjcard.2019.07.015. Epub 2019 Jul 24.
Characteristics and outcomes of patients with lymphoma undergoing percutaneous coronary intervention (PCI) are unknown. Therefore, we analyzed clinical characteristics and outcomes in patients that underwent PCI and had a concomitant diagnosis of Hodgkin's (HL) or non-Hodgkin's (NHL) lymphoma. We analyzed patients with and without lymphoma diagnosis from the Nationwide Inpatient Sample in the United States who underwent PCI procedure during 2004 to 2014. Multivariable regression analysis was performed to examine the association between lymphoma diagnosis and clinical outcomes post-PCI including short-term complications and in-hospital mortality. A total of 7,119,539 PCI procedures were included in the analysis and 18,052 patients had a diagnosis of lymphoma (0.25%). These patients were likely to experience in-hospital mortality (odds ratio [OR] 1.39, 95% confidence interval [CI] 1.25 to 1.54), stroke or transient ischemic attack (OR 1.75, 95% CI 1.61 to 1.90), and any in-hospital complication (OR 1.31, 95% CI 1.25 to 1.37), following PCI. In the lymphoma subtype-analysis, diagnosis of HL was associated with an increased odds of in-hospital death (OR 1.40, 95% CI 1.24 to 1.56), any in-hospital complication (OR 1.31, 95% CI 1.25 to 1.38), bleeding complications (OR 1.12 95% CI 1.05 to 1.20), and vascular complications (OR 1.13 95% CI 1.06 to 1.20) whereas these odds were not significantly associated with non-Hodgkin's diagnosis. Finally, both types of lymphoma were associated with increased odds of stroke/transient ischemic attack following PCI (OR 1.82, 95% CI 1.67 to 1.99 and OR 1.31, 95% CI 1.05 to 1.63, respectively). In conclusion, while the prevalence of lymphoma in the observed PCI cohort was low, a diagnosis of lymphoma was associated with an adverse prognosis following PCI, primarily in patients with the HL diagnosis.
在接受经皮冠状动脉介入治疗（PCI）的患者中，淋巴瘤的特征和结局尚不清楚。因此，我们分析了在美国国家住院患者样本中接受 PCI 治疗且同时诊断为霍奇金（HL）或非霍奇金淋巴瘤（NHL）的患者的临床特征和结局。我们分析了 2004 年至 2014 年期间接受 PCI 治疗且无或有淋巴瘤诊断的患者。多变量回归分析用于检查淋巴瘤诊断与 PCI 后短期并发症和院内死亡率等临床结局之间的关系。共纳入 7119539 例 PCI 手术，其中 18052 例患者被诊断为淋巴瘤（0.25%）。这些患者发生院内死亡率（比值比[OR]1.39，95%置信区间[CI]1.25 至 1.54）、卒中和短暂性脑缺血发作（OR 1.75，95%CI1.61 至 1.90）和任何院内并发症（OR 1.31，95%CI1.25 至 1.37）的可能性更高。在淋巴瘤亚型分析中，HL 诊断与院内死亡（OR1.40，95%CI1.24 至 1.56）、任何院内并发症（OR1.31，95%CI1.25 至 1.38）、出血并发症（OR1.12，95%CI1.05 至 1.20）和血管并发症（OR1.13，95%CI1.06 至 1.20）的可能性增加有关，但 NHL 诊断与这些结局无关。最后，两种类型的淋巴瘤与 PCI 后中风/短暂性脑缺血发作的风险增加相关（OR1.82，95%CI1.67 至 1.99 和 OR1.31，95%CI1.05 至 1.63）。总之，尽管观察到的 PCI 队列中淋巴瘤的患病率较低，但淋巴瘤的诊断与 PCI 后的不良预后相关，主要是在 HL 诊断的患者中。
